Genopathy
Gene-Disorder Association · Article
Gene
ABL1
ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase
Disorder
Chronic Myelogenous Leukemia, Bcr-Abl1 Positive
First reported 2002
Supporting publications 1
Key publication · gene–disorder Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.Blood · 2002
Key publication · disorder Ethyl carbamate (urethane) in the treatment of chronic myelocytic leukemia; results of a three-year study.The Medical clinics of North America · 1950
Manually curatedApproved treatment annotated
Association Review

In brief

The association between ABL1 (ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase) and Chronic Myelogenous Leukemia, Bcr-Abl1 Positive is well established and manually curated, with its 2 contributing sources — 1 of them expert-curated — recording pathogenic variants.

Sources 2
Clinical variants 10
Symptoms 0
Compounds 8
Trials 375of 1,807 via ABL1 compounds
Publications 1
01
At a glance

Association overview

A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.

Request access
02
Provenance

Evidence and sources

2 sources

Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.

Request access
03
ABL1

The gene

3 source summaries

A gene summary alongside the source descriptions it was distilled from.

Request access
04
Chronic Myelogenous Leukemia, Bcr-Abl1 Positive

The disorder

5 database identifiers

The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).

Request access
05
ClinVar and variant evidence

Genetic basis

10 clinical variants

ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.

Request access
06
Interventions

Therapeutics

8 compounds & drugs

Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.

Request access
07
Human studies

Clinical trials

1,807 clinical trials

Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.

Request access
08
Literature

Reading

1 publication

Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.

Request access
09
Provenance

References & sources

11 references

Every source and publication cited across this dossier, as one numbered reference list.

Request access